Madaus has marketed trospium chloride throughout Europe for over 20 years.
“We believe the position Madaus holds in the European market offers us the best opportunity to successfully commercialize Sanctura XR outside the US,” said Glenn Cooper, CEO of Indevus. “This agreement increases the economic opportunity for Indevus as Madaus currently markets trospium chloride through much of the world either directly or through co-promotion or distribution partners.”
Under the terms of the agreement, Madaus has the right to sell Sanctura XR outside the US except in Canada, Japan, Korea and China, where Indevus and Madaus will share equally in the economics. Madaus will pay Indevus a royalty on net sales and will purchase Sanctura XR from Indevus at cost plus a manufacturing margin based on units sold in the Madaus territories.
Separately the company said that Madaus has agreed to waive its rights under the original licensing agreement with Indevus to manufacture Sanctura XR in the US. Indevus will sell Sanctura XR to its partner Esprit Pharma for the US market.
In June and July 2006, the company reported positive results from the two phase III trials for Sanctura XR in overactive bladder.